Eratrectinib

Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC. It has been approved in June 2026 for use in treating for solid tumors in China.
Wikipedia contributors, "Eratrectinib", Wikipedia, revision 1370309205, retrieved 20 November 2026, source, CC BY-SA 4.0.